Rochester Regional Health/Unity Hospital, Rochester, NY, USA.
Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
Am J Cardiovasc Drugs. 2024 Jan;24(1):71-81. doi: 10.1007/s40256-023-00616-2. Epub 2023 Nov 23.
Cangrelor is a potent intravenous non-thienopyridine P2Y12 inhibitor. We conducted a network meta-analysis to study the efficacy and safety of cangrelor as compared with the oral P2Y12 inhibition, clopidogrel, or placebo in acute coronary syndromes.
This meta-analysis followed the Cochrane collaboration guidelines and the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) protocols. Outcomes of interest included all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, major bleeding, minor bleeding, and the need for blood transfusion.
The analysis was comprised of 6 studies including 26,444 patients treated with cangrelor, clopidogrel, or placebo. There were no statistically significant differences in the incidence of all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, or major bleeding. Cangrelor was associated with a higher risk of minor bleeding than clopidogrel or placebo, with no difference in requiring blood transfusion.
Cangrelor has comparable outcomes to clopidogrel in patients with acute coronary syndromes and can be used as a reliable alternative in this population.
坎格雷洛是一种强效的静脉内非噻吩吡啶 P2Y12 抑制剂。我们进行了一项网络荟萃分析，以研究坎格雷洛与口服 P2Y12 抑制剂氯吡格雷或安慰剂相比在急性冠状动脉综合征中的疗效和安全性。
这项荟萃分析遵循了 Cochrane 协作组指南和系统评价和荟萃分析的 Preferred Reporting Items（PRISMA）协议。感兴趣的结局包括全因死亡率、心肌梗死、支架血栓形成、靶血管血运重建、大出血、小出血和输血需求。
该分析包括 6 项研究，共纳入 26444 例接受坎格雷洛、氯吡格雷或安慰剂治疗的患者。全因死亡率、心肌梗死、支架血栓形成、靶血管血运重建或大出血的发生率无统计学差异。与氯吡格雷或安慰剂相比，坎格雷洛与小出血风险增加相关，但输血需求无差异。
坎格雷洛在急性冠状动脉综合征患者中的结局与氯吡格雷相当，可作为该人群的可靠替代药物。
